Cancer patients who got a COVID vaccine lived much longer

A groundbreaking new study has revealed that individuals battling advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of initiating immunotherapy treatment experienced significantly extended survival compared to those who did not. This pivotal finding, presented on October 19, 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, marks a potential paradigm shift in oncologic care and underscores the broader therapeutic potential of mRNA technology beyond infectious diseases.

A Milestone in Cancer Research

The research, a collaborative effort between scientists from the University of Florida (UF) and the University of Texas MD Anderson Cancer Center, represents a significant milestone in over a decade of dedicated work focused on developing mRNA-based treatments designed to activate the body’s intrinsic immune defenses against cancer. Building upon prior studies conducted at UF, these latest results offer a compelling step toward the eventual creation of a universal cancer vaccine, one capable of substantially enhancing the efficacy of existing immunotherapy regimens.

While the analysis, which scrutinized the medical records of more than 1,000 MD Anderson patients, remains preliminary, its implications are profound. Should these findings be substantiated by upcoming randomized clinical trials, the impact on global cancer care could be revolutionary, offering new hope to patients with limited treatment options.

Dr. Elias Sayour, M.D., Ph.D., a senior researcher on the study, a UF Health pediatric oncologist, and the Stop Children’s Cancer/Bonnie R. Freeman Professor for Pediatric Oncology Research, expressed immense optimism regarding the discovery. "The implications are extraordinary — this could revolutionize the entire field of oncologic care," Dr. Sayour stated. He further elaborated on the long-term vision: "We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients."

The Unexpected Connection: From Viral Defense to Cancer Treatment

The genesis of this remarkable discovery lies in the continued exploration of mRNA technology, a field that gained widespread public recognition during the COVID-19 pandemic. Jeff Coller, Ph.D., a distinguished mRNA expert at Johns Hopkins University, highlighted how this study exemplifies the unforeseen benefits of initiatives like Operation Warp Speed, the U.S. government’s rapid COVID-19 vaccine development program. "The results from this study demonstrate how powerful mRNA medicines truly are and that they are revolutionizing our treatment of cancer," Coller noted, underscoring the serendipitous expansion of mRNA applications.

Messenger RNA (mRNA) is a fundamental biological molecule present in every living cell, carrying genetic instructions from DNA to direct the synthesis of specific proteins. Sayour’s research, spanning eight years, has focused on combining lipid nanoparticles — tiny fat bubbles that protect and deliver mRNA — with various mRNA sequences to elicit immune responses.

A pivotal moment occurred in July when Sayour’s laboratory made an unexpected discovery. They found that to trigger a robust immune attack on cancer, it wasn’t strictly necessary to target a specific tumor protein, as had been the traditional approach in many cancer vaccine strategies. Instead, they realized they could simply stimulate the immune system to respond as if it were combating a viral infection. By pairing their experimental "nonspecific" mRNA vaccine with immune checkpoint inhibitors — a class of common cancer drugs that effectively "release the brakes" on the immune system, allowing it to better recognize and destroy tumor cells — the researchers observed a potent antitumor response in mouse models. Crucially, this experimental vaccine was not tailored to COVID-19 or any other specific virus or cancer, but it leveraged similar technological principles to the highly effective COVID-19 mRNA vaccines.

This breakthrough provided the intellectual spark for Dr. Adam Grippin, M.D., Ph.D., a former UF researcher now a scientist at MD Anderson, to pose a critical question: Could the existing COVID-19 mRNA vaccines, designed to elicit an antiviral immune response, have a similar immune-boosting effect in cancer patients already undergoing immunotherapy?

Observational Data Reveals Striking Survival Gains

To investigate this hypothesis, the research team undertook an extensive analysis of de-identified patient data. They meticulously reviewed medical records from patients treated at MD Anderson between 2019 and 2023. The focus was on individuals diagnosed with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma, two aggressive forms of cancer where immunotherapy has become a cornerstone of treatment but often faces challenges with patient responsiveness.

The findings were compelling. The analysis showed a clear association: patients who received a COVID-19 mRNA vaccine within a 100-day window, either before or after starting their immunotherapy regimen, survived significantly longer than their unvaccinated counterparts.

Detailed Survival Statistics:

• Advanced Lung Cancer: The study involved records of 180 advanced lung cancer patients who received a COVID-19 mRNA vaccine within the 100-day period relative to their immunotherapy initiation. This group was compared against 704 patients treated with the same immunotherapy drugs who did not receive the vaccine. The results were striking: receiving the mRNA vaccine was associated with a near doubling of median survival, extending it from 20.6 months to an impressive 37.3 months.

• Metastatic Melanoma: For metastatic melanoma patients, 43 individuals received an mRNA vaccine within 100 days of starting immunotherapy, while 167 patients did not. In the vaccinated group, median survival increased from 26.7 months to a range of 30 to 40 months. Researchers noted that at the time of data collection, some patients in the vaccinated melanoma cohort were still alive, suggesting the ultimate survival benefit could be even greater.

Significantly, the most pronounced improvements were observed in patients who, based on their tumor biology and other clinical factors, were not initially expected to respond strongly to immunotherapy. This suggests the mRNA vaccine might be "resetting" or "mobilizing" the immune system in a way that overcomes inherent resistance to standard treatments.

To further validate their findings and explore the underlying biological mechanisms, UF researchers conducted additional experiments using mouse models. They paired immunotherapy drugs with an mRNA vaccine specifically targeted at the COVID spike protein. These experiments demonstrated that the combination could effectively transform unresponsive cancers into responsive ones, successfully thwarting tumor growth.

Dr. Sayour elucidated the proposed mechanism: "One of the mechanisms for how this works is when you give an mRNA vaccine, that acts as a flare that starts moving all of these immune cells from bad areas like the tumor to good areas like the lymph nodes." This "flare" effect potentially primes the immune system, making it more alert and capable of engaging with the cancer cells that immunotherapy then helps expose. Importantly, the study also confirmed that receiving non-mRNA vaccines, such as those for pneumonia or influenza, did not result in similar improvements in longevity, underscoring the unique effect of the mRNA platform.

The Road Ahead: Confirmation Through Clinical Trials

Despite the compelling nature of these observational results, the researchers are acutely aware that further rigorous validation is essential. Duane Mitchell, M.D., Ph.D., Dr. Grippin’s doctoral mentor and the director of the UF Clinical and Translational Science Institute, emphasized this critical next step. "Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do," Dr. Mitchell stated. He added, "I think the urgency and importance of doing the confirmatory work can’t be overstated."

The immediate next step is to launch a large, randomized clinical trial. This crucial trial will be orchestrated through the UF-led OneFlorida+ Clinical Research Network, a robust consortium comprising hospitals, health centers, and clinics across Florida, Alabama, Georgia, Arkansas, California, and Minnesota. Such a widespread network is ideal for recruiting a diverse patient population and conducting a definitive study.

Dr. Betsy Shenkman, Ph.D., who leads the OneFlorida+ consortium, highlighted the network’s mission: "One of our key motivations at OneFlorida is to move discoveries from academic settings out into the real world and the places where patients get care." This commitment ensures that promising research quickly translates into tangible benefits for patients.

Broader Implications for Oncologic Care

If confirmed, these findings unlock numerous possibilities for the future of cancer treatment. The researchers envision the design of an even more potent "nonspecific universal vaccine." For patients grappling with advanced cancers, the prospect of increased survival from such a universal vaccine could offer an invaluable gift: more time – time with loved ones, time to pursue personal goals, and time for further scientific advancements.

"If this can double what we’re achieving currently, or even incrementally — 5%, 10% — that means a lot to those patients, especially if this can be leveraged across different cancers for different patients," said Dr. Sayour, who is also an investigator with UF’s McKnight Brain Institute. The ability to enhance the effectiveness of immunotherapy, particularly for patients who currently show limited response, would be transformative. It offers a potential avenue to broaden the applicability and success rates of these targeted treatments.

Context and the Evolution of mRNA Technology

The journey to this discovery underscores the remarkable evolution of mRNA technology. Initially explored for infectious diseases and vaccine development, the rapid success of COVID-19 mRNA vaccines validated the platform’s safety, efficacy, and scalability. This success has since catalyzed an explosion of research into mRNA applications for a wide range of other diseases, including cancer. The current study provides compelling evidence that the immune-priming capabilities of mRNA, initially harnessed to combat viruses, can be strategically repurposed to confront and overcome the complex challenges posed by malignant tumors.

The ability of mRNA vaccines to generate a robust innate immune response, mimicking a viral infection, appears to be key. This "danger signal" prompts immune cells to become more active and vigilant, potentially overcoming the immune evasion strategies employed by cancer cells. This mechanism suggests a departure from highly individualized, tumor-specific cancer vaccines towards a more generalized, "off-the-shelf" approach that could be broadly applicable across different cancer types and patient profiles.

Financial and Institutional Underpinnings

The extensive research leading to these findings was supported by significant funding from the National Cancer Institute and multiple foundational organizations, highlighting the collaborative investment in innovative cancer solutions. Furthermore, the intellectual property stemming from UF-developed mRNA vaccines is a testament to the institutional commitment to translating research into real-world applications. Drs. Sayour, Grippin, and Mitchell hold patents related to these UF-developed mRNA vaccines, which are licensed by iOncologi Inc., a biotech company that originated as a "spinout" from UF, in which Dr. Mitchell holds a vested interest. This intricate web of academic research, public funding, and private sector engagement exemplifies the multifaceted ecosystem required to bring such complex scientific advancements to fruition.

In conclusion, while the scientific community eagerly awaits the results of confirmatory randomized clinical trials, the initial findings from MD Anderson and the University of Florida offer a powerful beacon of hope. The potential to significantly extend the lives of patients with advanced lung and skin cancers by simply incorporating an mRNA vaccine into their treatment regimen could herald a new era in cancer care, fundamentally altering the landscape of oncologic treatment and patient outcomes worldwide.